Reduction in multiresistant nosocomial infections in neonates following substitution of ceftazidime with piperacillin/tazobactam in empiric antibiotic therapy.
OBJECTIVE
To evaluate the effect of a change in antibiotic protocol on pathogens that cause neonatal sepsis.


METHODS
Suspected sepsis was treated with amikacin together with ceftazidime in 1995-1998 and piperacillin/tazobactam in 1999-2002.


RESULTS
The annual rate for Klebsiella sepsis fell from 2.5 to 0.45 cases per 1000 admission days (p = 0.0001) between the two periods studied.


CONCLUSIONS
The change from ceftazidime to piperacillin/tazobactam is associated with a decrease in the incidence of Klebsiella sepsis.
Flidel-Rimon
O
O
Department of Neonatology, Kaplan Medical Center, Rehovot, Israel. orna_f@clalit.org.il
Friedman
S
S
Gradstein
S
S
Bardenstein
R
R
Shinwell
E S
ES
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002442:Ceftazidime / Q000627:therapeutic use; D003428:Cross Infection / Q000453:epidemiology / Q000517:prevention & control*; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D006801:Humans; D007231:Infant, Newborn; D017053:Infection Control; D007557:Israel / Q000453:epidemiology; D007710:Klebsiella Infections / Q000453:epidemiology / Q000517:prevention & control*; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D010878:Piperacillin / Q000627:therapeutic use*; D000077725:Piperacillin, Tazobactam Drug Combination
D000900:Anti-Bacterial Agents; D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D002442:Ceftazidime; D010878:Piperacillin